Prenetics Global (PRE) Reports 480% Revenue Surge Driven by IM8 Brand Launch

Prenetics Global Limited (NASDAQ:PRE) is one of the most promising micro-cap stocks according to analysts. On February 18, Prenetics Global Limited reported financial results for 2025, headlined by a 480% year-over-year revenue surge to $92.4 million. This was fueled by the company’s flagship health and longevity brand, IM8, which reached an ARR of $120 million within just one year of its launch. The Q4 alone saw revenue reach of $36.6 million, a 55% increase over the previous quarter, reflecting the market traction of the brand co-founded by David Beckham.

The company completed a major strategic transformation by divesting non-core assets, including ACT Genomics, the Europa distribution business, and its stake in Insighta. These moves, including a $70 million cash sale of the Insighta stake to Tencent, have fortified the balance sheet with ~$171 million in adjusted liquidity and zero debt. Furthermore, Prenetics ceased all cryptocurrency purchases, maintaining a permanent holding of 510 BTC, as it pivots to become a pure-play leader in the consumer health and nutrition sector.

Looking ahead to 2026, Prenetics Global Limited (NASDAQ:PRE) reaffirmed its revenue guidance for IM8 at $180 to $200 million, aiming for an ARR of up to $300 million by year-end. A key driver for this anticipated growth is a shift toward quarterly subscription models, which has already increased the average order value to ~$233 in early 2026.

Prenetics Global Limited (NASDAQ:PRE) is a health sciences company that advances consumer health in Hong Kong, the US, and internationally. It sells health & wellness products under the IM8 brand name, and provides fulfillment & distribution services for sports nutrition products under the Europa brand.

While we acknowledge the potential of PRE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Small Cap Tech Stocks With High Upside Potential.

Disclosure: None. Follow Insider Monkey on Google News.